SOPHiA GENETICS SA (SOPH) Institutional Buying & Selling Tracker (Q2 2026)

SOPH ranks #5307 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

72 institutions disclose a position in SOPH, but none treat it as a major bet — even Alta Wealth Advisors LLC, its most concentrated holder, allocates just 2.2% of its own portfolio to it.

Royce & Associates LP has added to its SOPH position for two straight quarters, increasing it by $17.5M to reach $19.5M today.

Rathbones Group PLC has trimmed its SOPH position for two straight quarters, cutting it by $100.8K while still holding $647.0K.

SOPH is down 1.7% today, but institutions show net buying of $75.1M this quarter — a divergence between today's price move and the underlying institutional flow.

SOPH reported a net loss of $79.0M in its latest fiscal year.

• Not yet profitable — net loss of $79.0M in the latest fiscal year
• Revenue grew 18.6% year over year
• Net income declined year over year, from -$62.5M to -$79.0M
• Operating cash flow was negative, using $35.9M in cash
• Current ratio of 1.96x — enough short-term assets to cover short-term liabilities
• Liabilities run 2.46x equity — a highly leveraged balance sheet worth noting